Document Detail

Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure.
MedLine Citation:
PMID:  8803516     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To study the haemodynamic profile and tolerability of imidapril, a new long-acting ACE inhibitor, and to investigate the effect of inhibition of circulating ACE on blood pressure in patients with stable chronic heart failure. METHODS: Twenty-four patients with stable, chronic heart failure (New York Heart Association (NYHA) functional Class II-III) were randomised to receive either 2.5 mg or 5 mg imidapril. Other vasodilators were withheld for > or = 5 half-lives. Blood pressure and ACE activity were carefully monitored for 24 h after dosing. RESULTS: Both 2.5 mg and 5 mg imidapril decreased systolic blood pressure, while diastolic blood pressure fell only after 5 mg imidapril. The two doses produced a significant and similar inhibition of circulating (serum) ACE. No serious adverse effects were observed, although symptomatic hypotension occured in 1 patient (5 mg). The decrease in blood pressure was not related to baseline ACE activity, serum sodium or serum creatinine concentration. CONCLUSIONS: Imidapril significantly lowered systolic blood pressure and was well tolerated. The difference in the first dose response to the two doses with respect to diastolic blood pressure suggests that this haemodynamic effect of ACE-inhibition is not related to inhibition of circulating ACE.
Y M Pinto; D J van Veldhuisen; R T Tjon-Ka-Jie; G Rooks; T Netzer; K I Lie
Related Documents :
10986156 - Rationale for angiotensin ii receptor blockers in patients with low-renin hypertension.
23350046 - Observations of acid reflux and motor function in distal esophagus using simultaneous m...
2404266 - Ace inhibitors. a safe option for hypertension and congestive heart failure.
11847186 - Blood pressure and nacl-sensitive hypertension are influenced by angiotensin-converting...
23700986 - Hypertonic sodium bicarbonate versus intravenous lipid emulsion in a rabbit model of in...
12804056 - Intraocular adenosine levels in normal and ocular-hypertensive patients.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  50     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1996  
Date Detail:
Created Date:  1996-11-27     Completed Date:  1996-11-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  265-8     Citation Subset:  IM    
Department of Cardiology/Thoraxcenter, University Hospital Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Analysis of Variance
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
Antihypertensive Agents / administration & dosage*
Blood Pressure / drug effects*
Chronic Disease
Double-Blind Method
Heart Failure / drug therapy*
Imidazoles / administration & dosage*
Middle Aged
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Imidazoles; 0/Imidazolidines; 89396-94-1/imidapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, comp...
Next Document:  Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antag...